You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥治療晚期結直腸癌藥獲納入新版國家醫保藥品目錄
阿思達克 12-10 11:30

長和(00001.HK)公布,旗下和黃醫藥用於治療晚期結直腸癌的國家 1類創新標靶抗癌藥物愛優特,已獲納入醫保局公佈的新版國家醫保藥品目錄,其可及性將延展至內地所有省份,並將於2020年1月1日開始,在各大公立醫院藥房上架。

愛優特是次獲納入醫保藥品目錄,標誌著和黃醫藥將進一步提升愛優特在內地市場的覆蓋和可及性。

愛優特是和黃醫藥在內地上市的首款抗腫瘤新藥,同時是抗腫瘤治療主流領域首個從發現、研發到無附加條件獲批均在中國完成的藥物。自2018年11月推出市場以來,已累計幫助了數千名患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account